UBS, PWC: Advisory on CVC Capital Partners’ Acquisition of Therakos for $925m

UBS, alongside PWC, played a pivotal role in advising on the recent acquisition of Mallinckrodt’s Therakos business by CVC Capital Partners, a deal valued at $925 million.

This strategic move is part of Mallinckrodt’s broader initiative to streamline its operations and focus on its core competencies in specialty pharmaceuticals.

Therakos is renowned for its